What Are the Early Signs of Tardive Dyskinesia from Reglan?
From General Health Literacy to Specific Medication Risks
If you or a loved one has taken Reglan and noticed uncontrollable facial movements, you may be seeing early signs of tardive dyskinesia. The medical community has long recognized that certain medications can trigger movement disorders, and Reglan—a drug used for stomach motility—carries a known risk. This page explains how to recognize symptoms and what to do next.
Reglan and Tardive Dyskinesia: Medical Evidence and FDA Warnings
Reglan (metoclopramide) is a medication approved for short-term use in adults with symptomatic gastroesophageal reflux that has not responded to conventional therapy, and for relief of symptoms in adults with acute and recurrent diabetic gastroparesis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The FDA-approved labeling includes a boxed warning stating that metoclopramide, including Reglan, can cause tardive dyskinesia (TD), a potentially irreversible serious movement disorder (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). TD is characterized by involuntary, repetitive movements of the face, tongue, trunk, and extremities, and may be disfiguring (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The risk of developing TD increases with longer duration of treatment and higher total cumulative dosage of metoclopramide (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Reglan is contraindicated in patients with a history of TD (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The labeling instructs healthcare providers to use Reglan for the shortest duration necessary and to periodically reassess the need for continued treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For patients with symptomatic, documented gastroesophageal reflux, the maximum approved duration of Reglan treatment is 12 weeks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). In patients with diabetic gastroparesis, the labeling advises avoiding total treatment duration longer than 12 weeks; if longer-term use is unavoidable, routine monitoring for signs and symptoms of TD is recommended (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Reglan tablets are not recommended for use in pediatric patients due to the risk of developing TD and other extrapyramidal symptoms (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The mechanistic pathway linking Reglan to TD involves metoclopramide's dopamine D2 receptor antagonism in the basal ganglia, which can lead to supersensitivity of dopamine receptors and subsequent involuntary movements. The labeling notes that metoclopramide may suppress or partially suppress the signs of TD, potentially delaying diagnosis by masking the underlying disease process (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). If signs or symptoms of TD develop, Reglan should be immediately discontinued (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The labeling also warns against concomitant use of other drugs known to cause TD, extrapyramidal symptoms, or neuroleptic malignant syndrome, and advises avoiding use in patients with Parkinson's disease (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).
Statute of Limitations for Reglan Claims in Washington
For patients in Washington who have developed TD after using Reglan, attorney-related considerations include the statute of limitations, which is the time window within which a lawsuit must be filed. The statute of limitations for personal injury claims in Washington is generally three years from the date the injury was discovered or reasonably should have been discovered. However, the timeline between exposure to Reglan and documented harm can be complex. TD may not appear until months or years after starting metoclopramide, and symptoms can be subtle initially, such as mild facial twitching or tongue movements. The labeling emphasizes that the risk increases with duration of treatment and cumulative dosage, meaning patients who used Reglan for longer than the recommended 12-week period may be at higher risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The adequacy of warnings is a key risk anchor: the boxed warning clearly states the risk of TD, but questions may arise about whether prescribers and patients were adequately informed about the need for short-term use only and the importance of monitoring. If a patient was prescribed Reglan for longer than 12 weeks without proper reassessment, or if they were not warned about the risk of TD, this could be relevant in legal evaluation. Attorney-related considerations also involve documenting the timeline of Reglan use, onset of TD symptoms, and any medical records showing whether the prescribing physician followed FDA-recommended guidelines. The labeling's limitation of use for gastroesophageal reflux to 12 weeks and the caution for diabetic gastroparesis are critical points (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Patients who developed TD after prolonged use may have a stronger basis for legal action if they can demonstrate that the prescribing physician deviated from standard care. Additionally, the boxed warning's instruction to discontinue Reglan immediately if TD signs appear (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397) underscores the importance of timely diagnosis. Delayed diagnosis, possibly due to the masking effect of metoclopramide, can affect the statute of limitations clock, as the injury may not be discovered until later. In summary, the evidence from the FDA-approved labeling establishes that Reglan carries a known risk of TD, with specific warnings about duration of use and cumulative dosage. For affected patients in Washington, the statute of limitations requires prompt legal consultation to assess the timeline of exposure and harm. The adequacy of warnings and adherence to prescribing guidelines are central to evaluating potential claims.
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Frequently Asked Questions
What is the statute of limitations for Reglan tardive dyskinesia claims in Washington?
In Washington, the statute of limitations for personal injury claims, including those related to Reglan-induced tardive dyskinesia, is generally three years from the date the injury was discovered or reasonably should have been discovered. Because TD symptoms may appear months or years after Reglan use, it is crucial to consult an attorney promptly to determine the applicable deadline.
How does the FDA labeling of Reglan affect legal claims for tardive dyskinesia?
The FDA-approved labeling for Reglan includes a boxed warning about the risk of tardive dyskinesia, emphasizing that the risk increases with longer treatment duration and higher cumulative doses. The labeling limits use for gastroesophageal reflux to 12 weeks and advises against longer use for diabetic gastroparesis. If a physician prescribed Reglan beyond these guidelines without proper monitoring or warning, it may support a claim of inadequate warnings or deviation from standard care.
Does submitting information create an attorney-client relationship?
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
Related Articles
References
Request a Free Case Review
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.